Fulgent Genetics, Inc. (FLGT)

Market Cap	610.70M
Revenue (ttm)	292.45M
Net Income (ttm)	-40.78M
Shares Out	30.44M
EPS (ttm)	-1.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	87,696
Open	20.10
Previous Close	20.10
Day's Range	19.98 - 20.24
52-Week Range	14.57 - 25.11
Beta	1.04
Analysts	Buy
Price Target	24.00 (+19.64%)
Earnings Date	Aug 1, 2025

About FLGT

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive he...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Sep 29, 2016
• Employees: 1,313
• Stock Exchange: NASDAQ
• Ticker Symbol: FLGT
• Website: https://www.fulgentgenetics.com

Financial Performance

In 2024, Fulgent Genetics's revenue was $283.47 million, a decrease of -1.99% compared to the previous year's $289.21 million. Losses were -$42.71 million, -74.55% less than in 2023.

Analyst Summary

According to 2 analysts, the average rating for FLGT stock is "Buy." The 12-month stock price target is $24.0, which is an increase of 19.64% from the latest price.

Price Target

$24.0

(19.64% upside)

Analyst Consensus: Buy